单位：[a]Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Ohio, USA[b]University of Giessen and Marburg Lung Center, German Center of Lung Research (DZL), Giessen, Germany[c]Department ofPneumology, Kerckhoff-Klinik, Bad Nauheim, Germany[d]Department of Medicine, Imperial College London, London,UK[e]Centre for Pulmonary Hypertension, Thoraxklinik at Heidelberg University Hospital, German Center of LungResearch (DZL), Heidelberg, Germany[f]Department of Respiratory Medicine, Hannover Medical School, German Centerof Lung Research (DZL), Hannover, Germany[g]2nd Department of Medicine − Department of Cardiovascular Medicine,First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic[h]Department ofCardiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, ChineseAcademy of Medical Sciences and Peking Union Medical College, Beijing, China[i]Division of Pulmonary and CriticalCare Medicine, University of California San Diego, La Jolla, California,[j]Centre for Pulmonary Vascular Disease andLady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada[k]Centre de Ref erence del'Hypertension Pulmonaire Severe, Service de Pneumologie et Reanimation, H^opital Bic^etre, Universite Paris-Saclay, LeKremlin-Bic^etre, France[l]INSERM UMR_S999, LabEx LERMIT, H^opital Marie Lannelongue, Le Plessis-Robinson,France[m]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan FriendshipHospital, Beijing, China[n]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China[o]National Clinical Research Center for Respiratory Diseases, Beijing, China[p]Chinese Academy of Medical Sciences, PekingUnion Medica, Beijing, China[q]WHO Collaboration Center for Tobacco Cessation and Respiratory Diseases Prevention,Beijing, China[r]Employee of Chrestos Concept GmbH & Co. KG, Essen, Germany[s]Division of Cardiology, FondazioneIRCCS Policlinico S Matteo, Pavia, Italy[t]Global Medical Affairs, Bayer AG, Berlin, Germany.
BACKGROUND: In the Phase III PATENT-1 (NCT00810693) and CHEST-1 (NCT00855465) studies, riociguat demonstrated efficacy vs placebo in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Clinical effects were maintained at 2 years in the long-term extension studies PATENT-2 (NCT00863681) and CHEST-2 (NCT00910429). METHODS: This post hoc analysis of hemodynamic data from PATENT-1 and CHEST-1 assessed whether riociguat improved right ventricular (RV) function parameters including stroke volume index (SVI), stroke volume, RV work index, and cardiac efficiency. REVEAL Risk Score (RRS) was calculated for patients stratified by SVI and right atrial pressure (RAP) at baseline and follow-up. The association between RV function parameters and SVI and RAP stratification with long-term outcomes was assessed. RESULTS: In PATENT-1 (n = 341) and CHEST-1 (n = 238), riociguat improved RV function parameters vs placebo (p < 0.05). At follow-up, there were significant differences in RRS between patients with favorable and unfavorable SVI and RAP, irrespective of treatment arm (p < 0.0001). Multiple RV function parameters at baseline and follow-up were associated with survival and clinical worsening-free survival (CWFS) in PATENT-2 (n = 396; p < 0.05) and CHEST-2 (n = 237). In PATENT-2, favorable SVI and RAP at follow-up only was associated with survival and CWFS (p < 0.05), while in CHEST-2, favorable SVI and RAP at baseline and follow-up were associated with survival and CWFS (p < 0.05). CONCLUSION: This post hoc analysis of PATENT and CHEST suggests that riociguat improves RV function in patients with PAH and CTEPH. (C) 2021 The Author(s). Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.
基金：
Bayer AG (Berlin, Germany); Merck & Co., Inc., Kenilworth, NJ, USA; Good Publications Practice (GPP3) guidelines
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2020]版：
大类|1 区医学
小类|1 区外科1 区移植2 区心脏和心血管系统2 区呼吸系统
最新[2025]版：
大类|1 区医学
小类|1 区外科1 区移植2 区心脏和心血管系统2 区呼吸系统
JCR分区：
出版当年[2019]版：
Q1TRANSPLANTATIONQ1RESPIRATORY SYSTEMQ1SURGERYQ1CARDIAC & CARDIOVASCULAR SYSTEMS
第一作者单位：[a]Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Ohio, USA[*a]Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, 473 W. 12th Avenue, Suite 200, Columbus, OH 43210
通讯作者：
通讯机构：[a]Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Ohio, USA[*a]Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, 473 W. 12th Avenue, Suite 200, Columbus, OH 43210
推荐引用方式(GB/T 7714)：
Raymond L. Benza,Hossein-Ardeschir Ghofrani,Ekkehard Gr€unig,et al.Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension[J].JOURNAL of HEART and LUNG TRANSPLANTATION.2021,40(10):1172-1180.doi:10.1016/j.healun.2021.06.020.
APA：
Raymond L. Benza,Hossein-Ardeschir Ghofrani,Ekkehard Gr€unig,Marius M. Hoeper,Pavel Jansa...&Stefano Ghio.(2021).Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.JOURNAL of HEART and LUNG TRANSPLANTATION,40,(10)
MLA：
Raymond L. Benza,et al."Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension".JOURNAL of HEART and LUNG TRANSPLANTATION 40..10(2021):1172-1180
医学